On August 6, 2026, a Texas federal court dismissed an antitrust lawsuit brought by compounding pharmacy Strive Specialties Inc. against pharmaceutical giants Eli Lilly and Novo Nordisk. The court determined that Strive Specialties Inc. failed to adequately allege that the two companies blocked market competition for GLP-1 medications, leading to the dismissal of the legal claims.
Texas antitrust lawsuit dismissal
- ▪The Texas federal court's dismissal of the antitrust lawsuit against Eli Lilly and Novo Nordisk was issued on August 6, 2026.
- ▪A Texas federal court dismissed an antitrust lawsuit filed by Strive Specialties Inc. against Eli Lilly and Novo Nordisk.
GLP-1 medication market competition
- ▪The Texas federal court determined that Strive Specialties Inc. failed to allege that Eli Lilly and Novo Nordisk blocked market competition.
- ▪The antitrust dispute between Strive Specialties Inc. and the pharmaceutical companies Eli Lilly and Novo Nordisk centered on competition for GLP-1 medications.
Compounding pharmacy legal claims
- ▪The legal claims brought by compounding pharmacy Strive Specialties Inc. targeted Eli Lilly and Novo Nordisk as defendants.
- ▪A Texas federal court dismissed an antitrust lawsuit filed by Strive Specialties Inc. against Eli Lilly and Novo Nordisk.
Story comments
Loading comments…